Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Efficacy and safety of recombinant human epidermal growth factor combined with fractional carbon dioxide laser for facial atrophic acne scars: a systematic review and meta-analysis of randomized trials

Zhou S., Guo C., Zhai J., Zhang Y.

Meta-analysis with a reported sample of 44 on Scar, published in Lasers Med Sci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Lasers Med Sci (2026)
Reported sample size
44
Source database
Europe PMC
PMID
42168448
PMCID
PMC13194242
DOI
10.1007/s10103-026-04881-w

Abstract (original English)

Background The combination of recombinant human epidermal growth factor (rhEGF) and fractional carbon dioxide (CO 2 ) laser therapy is increasingly used in the treatment of facial atrophic acne scars. Objective This study aimed to systematically assess the efficacy and safety of rhEGF combined with fractional CO 2 laser therapy for managing facial atrophic acne scars. Methods PubMed, Embase, the Cochrane Library, Web of Science, CNKI (China National Knowledge Infrastructure), Wanfang, SinoMed, and VIP were searched from inception to July 29, 2025. Parallel-group or split-face randomized controlled trials (RCTs) comparing fractional CO 2 laser therapy + rhEGF with fractional CO 2 laser therapy for treating atrophic acne scars were considered for inclusion. Risk of bias was assessed using the Cochrane Collaboration's risk-of-bias tool. The meta-analysis based on fixed or random effects models was carried out for Echelle d'Evaluation Clinique des Cicatrices d'acne (ECCA) scores, Vancouver Scar Scale (VSS) scores, transepidermal water loss (TEWL), etc. It was registered on PROSPERO (ID: CRD42024599311). Results Twelve RCTs involving 1,044 patients were included, and all trials were conducted in China. Follow-up durations across studies ranged from 1 week to 12 months. Compared with fractional CO₂ laser therapy alone, the combination therapy significantly reduced ECCA scores by a me

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
FaceCicatrixHumansAcne VulgarisAtrophyEpidermal Growth FactorRecombinant ProteinsTreatment OutcomeCombined Modality TherapyRandomized Controlled Trials as Topic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research